B 9430

Known as: B-9430 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2016
01219972016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
We have previously reported the design, pharmacological properties and imaging application of bradykinin (BK) B2 receptor (B2R… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2008
2008
B-9430 (d-Arg-[Hyp3, Igl5, D-Igl7, Oic8]-bradykinin), where Hyp is trans-4-hydroxyproline, Igl is alpha-(2-indanyl)glycine and… (More)
  • figure 1
  • figure 2
Is this relevant?
2007
2007
The bradykinin B(2) receptor is a heptahelical receptor regulated by a cycle of phosphorylation, endocytosis, and extensive… (More)
Is this relevant?
2004
2004
Angiotensin-converting enzyme inhibition (ACEI) with captopril has been shown to increase water intake and urine output in rats… (More)
  • table 2
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2003
2003
The aim of the present study was to evaluate the influence of bradykinin on microcirculatory changes and outcome after global… (More)
Is this relevant?
2000
2000
The influence of the bradykinin B1/B2 antagonist B 9430 on the cerebral microcirculation following global cerebral ischemia was… (More)
Is this relevant?
1997
1997
Extensive proton magnetic resonance experiments were carried out on three bradykinin peptide antagonists B-9430, B-9436, and B… (More)
Is this relevant?
1997
1997
Inflammatory disorders typically have a complex etiology and involve a multitude of inflammatory mediators, and hence, a… (More)
Is this relevant?